A person with a two hour history of phlegmasia cerulea dolens (left leg, right side of image)
Phlegmasia cerulea dolens (PCD) (literally: 'painful blue inflammation'), not to be confused with preceding phlegmasia alba dolens, is an uncommon severe form of lower extremity deep venous thrombosis (DVT) that obstructs blood outflow from a vein. Upper extremity PCD is less common, occurring in under 10% of all cases.[1] PCD results from extensive thrombotic occlusion (blockage by a thrombus) of extremity veins, most commonly an iliofemoral DVT, of the iliac vein and/or common femoral vein.[2][3] It is a medical emergency requiring immediate evaluation and treatment.
It is characterized by progressive lower extremity edema distal to the thigh, tight shiny skin, cyanosis (inadequate blood oxygenation), petechiae or purpura, and sudden severe pain of the affected limb in proportion to the level of venous blockage. Patients often have difficulty walking. Blisters, bullae, paresthesias, and motor weakness may develop in severe cases, along with gangrene in ~50% of cases.[4][5] Distal pulses are palpable early on but may diminish over time, and doppler signal can be usually heard throughout disease progression.[6] The left limb is more commonly affected due to its vascular anatomy (the right internal iliac artery directly overlies the left iliac vein).[7][8]
Deep vein thrombosis of the left external iliac in a person with bladder cancer resulting in this condition. (Author James Heilman, MD, 2016)
Pathophysiology
When a thrombus occludes an extremity vein, pressure backs up in the venous system leading plasma fluid to leak out into the interstitium of the affected limb. This increases the pressure of that limb compartment, which can collapse the arteries and lead to acute ischemia, gangrene, hypovolemia, and hemodynamic instability.[14][15]
Diagnosis
PCD is best diagnosed with contrast venography, but venous duplex ultrasonography is used more commonly in clinical practice. Magnetic resonance and computed tomography venography can also be used.[16]
PCD is fully reversible if the causal venous thrombus is promptly removed.[23] In the 40-60% of people who go on to develop venous gangrene, there is a 20-50% risk of amputation and 20-40% mortality rate.[24][25] Following PCD resolution patients are more likely to develop venous insufficiency and post-thrombotic syndrome[26]
Grade I = non-complicated (no blistering, strong sensory-motor function and strong distal pulses)
Grade II = impending venous gangrene (blistering, weak sensory-motor function and weak distal pulses)
Grade III = venous gangrene
Epidemiology
PCD is most likely to occur in people in their 50s and 60s, but can occur as early as 6 months old. There is slight male predominance of around 1.5:1.[29][30]
History
This phenomenon was first discovered by Fabricus Hildanius in the 16th century, and was officially termed "phlegmasia cerulea dolens" by Gregoire in 1938.[31][32]Phlegmasia originates from the Greek root phlegma (inflammation), cerulea originates from Latin root caeruleus (dark blue), and dolens originates from Latin word dolens (suffering).[33]
↑ Rutherford's vascular surgery and endovascular therapy. Anton N. Sidawy, Bruce A. Perler (9thed.). Philadelphia, PA. 2019. ISBN978-0-323-58130-1. OCLC1037557259.{{cite book}}: CS1 maint: location missing publisher (link) CS1 maint: others (link)
↑ Rutherford's vascular surgery and endovascular therapy. Anton N. Sidawy, Bruce A. Perler (9thed.). Philadelphia, PA. 2019. ISBN978-0-323-58130-1. OCLC1037557259.{{cite book}}: CS1 maint: location missing publisher (link) CS1 maint: others (link)
↑ Rutherford's vascular surgery and endovascular therapy. Anton N. Sidawy, Bruce A. Perler (9thed.). Philadelphia, PA. 2019. ISBN978-0-323-58130-1. OCLC1037557259.{{cite book}}: CS1 maint: location missing publisher (link) CS1 maint: others (link)
↑ Chang, Grace; Yeh, James J. (July 2014). "Fulminant phlegmasia cerulea dolens with concurrent cholangiocarcinoma and a lupus anticoagulant: a case report and review of the literature". Blood Coagulation & Fibrinolysis. 25 (5): 507–511. doi:10.1097/MBC.0000000000000057. ISSN1473-5733. PMID24553060. S2CID10642849.
↑ Rutherford's vascular surgery and endovascular therapy. Anton N. Sidawy, Bruce A. Perler (9thed.). Philadelphia, PA. 2019. ISBN978-0-323-58130-1. OCLC1037557259.{{cite book}}: CS1 maint: location missing publisher (link) CS1 maint: others (link)
↑ Chang, Grace; Yeh, James J. (July 2014). "Fulminant phlegmasia cerulea dolens with concurrent cholangiocarcinoma and a lupus anticoagulant: a case report and review of the literature". Blood Coagulation & Fibrinolysis. 25 (5): 507–511. doi:10.1097/MBC.0000000000000057. ISSN1473-5733. PMID24553060. S2CID10642849.
↑ Rutherford's vascular surgery and endovascular therapy. Anton N. Sidawy, Bruce A. Perler (9thed.). Philadelphia, PA. 2019. ISBN978-0-323-58130-1. OCLC1037557259.{{cite book}}: CS1 maint: location missing publisher (link) CS1 maint: others (link)
↑ Chang, Grace; Yeh, James J. (July 2014). "Fulminant phlegmasia cerulea dolens with concurrent cholangiocarcinoma and a lupus anticoagulant: a case report and review of the literature". Blood Coagulation & Fibrinolysis. 25 (5): 507–511. doi:10.1097/MBC.0000000000000057. ISSN1473-5733. PMID24553060. S2CID10642849.
↑ Rutherford's vascular surgery and endovascular therapy. Anton N. Sidawy, Bruce A. Perler (9thed.). Philadelphia, PA. 2019. ISBN978-0-323-58130-1. OCLC1037557259.{{cite book}}: CS1 maint: location missing publisher (link) CS1 maint: others (link)
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.